Genentech's rheumatoid arthritis biologic gains FDA approval

01/10/2010 | San Francisco Chronicle

The FDA approved Genentech's Actemra, the only rheumatoid arthritis drug that targets the interleukin-6 protein, which plays a role in joint inflammation. The treatment is expected to benefit patients who do not respond to Remicade, Humira or Enbrel, which target an inflammatory protein called tumor necrosis factor-alpha.

View Full Article in:

San Francisco Chronicle

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC